ADC deal-making continues despite ImmunoGen trauma
This article was originally published in Scrip
Executive Summary
ADC Therapeutics has licensed antibodies from Five Prime Therapeutics to develop antibody-drug conjugates (ADCs). ADCs are now a major focus for deal activity following the approval earlier this year of Kadcyla, the Genentech (Roche) ADC that links the blockbuster oncology drug Herceptin and a targeted chemotherapy agent developed by ImmunoGen.